Nicholas Conrad Smith bought $25k of ANRO
CHIEF FINANCIAL OFFICER at Alto Neuroscience, Inc.. 1,563 shares at an average of $16.00, traded Feb 6, 2024, filed Feb 7, 2024.
Score components
- +22RoleCFO
- +5Trade size$25k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +10Price context0% above the 52-week low
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-002940, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 6, 2024 | POpen-market purchase Common Stock | +1,563 | $16.00 | $25k | 1,563 | Feb 7, 2024 |
Related signals
Other insiders at Alto Neuroscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | Alto Neuroscience, Inc. | Nicholas Conrad Smith PRESIDENT AND CFO | $3.6M 134,886 shares | -100% | |
| 45Moderate | ANRObuy Alto Neuroscience, Inc. | Adam Savitz CHIEF MEDICAL OFFICER | $191k 15,000 shares | +60% | |
| 47Moderate | ANRObuy Alto Neuroscience, Inc. | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | $101k 6,150 shares | +30% | |
| 60Notable | Alto Neuroscience, Inc. | Alpha Wave Global, LP owner | $9.6M 600,000 shares | +19% | |
| 52Moderate | Alto Neuroscience, Inc. | Amit Etkin PRESIDENT AND CEO | $50k 3,125 shares | +0% | |
| 63Notable | Alto Neuroscience, Inc. | Adam Savitz CHIEF MEDICAL OFFICER | $272k 17,000 shares | +217% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.